Basit öğe kaydını göster

Infliximab does not suppress the tuberculin skin test (purified protein derivative)

dc.contributor.authorTascilar, Koray
dc.contributor.authorHatemi, Gulen
dc.contributor.authorMasatlioglu, Seval
dc.contributor.authorYazici, Hasan
dc.contributor.authorMelikoglu, Melike
dc.contributor.authorFresko, Izzet
dc.date.accessioned2021-03-05T16:07:42Z
dc.date.available2021-03-05T16:07:42Z
dc.date.issued2007
dc.identifier.citationHatemi G., Melikoglu M., Fresko I., Masatlioglu S., Tascilar K., Yazici H., "Infliximab does not suppress the tuberculin skin test (purified protein derivative)", JOURNAL OF RHEUMATOLOGY, cilt.34, ss.474-480, 2007
dc.identifier.issn0315-162X
dc.identifier.othervv_1032021
dc.identifier.otherav_bf27439b-5c32-4157-ba53-8bbd3fddadf1
dc.identifier.urihttp://hdl.handle.net/20.500.12627/126931
dc.description.abstractObjective. Tuberculin skin testing with purified protein derivative (PPD) is part of tuberculosis (TB) screening in patients receiving infliximab. We assessed whether infliximab, a strong inhibitor of inflammation, suppressed dermal induration, the outcome of this test. We also reassessed the booster phenomenon and the interobserver variability in tuberculin testing.
dc.language.isoeng
dc.subjectİmmünoloji ve Romatoloji
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.titleInfliximab does not suppress the tuberculin skin test (purified protein derivative)
dc.typeMakale
dc.relation.journalJOURNAL OF RHEUMATOLOGY
dc.contributor.department, ,
dc.identifier.volume34
dc.identifier.issue3
dc.identifier.startpage474
dc.identifier.endpage480
dc.contributor.firstauthorID182106


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster